Roivant Sciences Ltd(ROIV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:04 AM ET (Korea 10/27 17:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.44 | Insider Own | 27.42% | Shs Outstand | 722.7M | Perf Week | 3.89% |
| Market Cap | 26.04B | Forward P/E | - | EPS next Y | 4.98% | Insider Trans | -3.78% | Shs Float | 524.3M | Perf Month | 0.7% |
| Enterprise Value | 22.99B | PEG | - | EPS next Q | -0.37 | Inst Own | 76.34% | Short Float | 7.5% | Perf Quarter | 6.53% |
| Income | -0.27B | P/S | 3458.12 | EPS this Y | -154.96% | Inst Trans | 3.25% | Short Ratio | 5.26 | Perf Half Y | 29.44% |
| Sales | 0.01B | P/B | 6.16 | EPS next 5Y | 5.61% | ROA | -5.15% | Short Interest | 39.30M | Perf YTD | 66.13% |
| Book/sh | 5.86 | P/C | 6.77 | EPS past 3/5Y | 32.67% 34.68% | ROE | -6.21% | 52W High | -15.18% ($42.50) | Perf Year | 97.86% |
| Cash/sh | 5.32 | P/FCF | - | Sales past 3/5Y | -48.73% -19.07% | ROIC | -6.15% | 52W Low | 101.51% ($17.89) | Perf 3Y | 326.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.61% | Gross Margin | 43.37% | Volatility(W/M) | 4.32% 3.7% | Perf 5Y | 328.66% |
| Dividend TTM | - | EV/Sales | 3053.27 | Sales Y/Y TTM | -67.58% | Oper. Margin | -18146.12% | ATR (14) | 1.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.72 | EPS Q/Q | 19.77% | Profit Margin | -3534.96% | RSI (14) | 51.07 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.72 | Sales Q/Q | -33.55% | SMA20 | 2.19% ($35.28) | Beta | 1.23 | Target Price | $48.91 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/9 | SMA50 | -1.61% ($36.64) | Rel Volume | 1.32 | Prev Close | $36.49 |
| Employees | 721 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -11.72% -29.89% | SMA200 | 15.48% ($31.22) | Avg Volume(3M) | 7.47M | Price | $36.05 |
| IPO | 2020/12/8 | Option/Short | Yes/Yes | Trades | 37601 | Volume | 9,869,018 | Change | -1.21% |
🧬 Roivant Sciences (ROIV) is a global biopharmaceutical holding company that develops a diverse portfolio of targeted therapeutics based on its unique "Vant" model. By operating independent disease-specific subsidiaries, it maximizes the speed of new drug candidate development and creates high added value through technology outlicensing and equity sales to pharmaceutical companies.
Over the past 1 year, roughly in the middle
15% below its 1-year high.
Traded more than usual. That is 132% of its average volume.
Next earnings report: November 9
13 days to go.
ROIV has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -155.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $345,812. Peers typically go for $906. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +328.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 76.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #10 of 594 in the industry
Based on market cap of $26B.
ALNY#7 Alnylam Pharmaceuticals Inc $30B PER 38.4 
RPRX#8 Royalty Pharma plc $29B PER 34.5 
GMAB#9 Genmab ADR $27B PER 35.4 ROIV#10 Roivant Sciences Ltd $26B PER - 
INCY#11 Incyte Corp $23B PER 14.4 
FAQ
What kind of company is ROIV?
ROIV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ROIV?
The market cap of ROIV is approximately $26.0B, ranking 511 within its sector.
What is the 52-week high and low for ROIV?
ROIV has recorded a 52-week high of $42.50 and a low of $17.89.
